Cheng "Cynthia" Li leads business and corporate development at Spotlight Therapeutics and is a member of Spotlight's leadership team. In this role, Cynthia's responsibilities span business development, licensing, and alliance management, as well as corporate strategy and investor relations.
Cynthia brings over 10 years of oncology research, pharma, and biotech experience, with core expertise in BD&L, and commercial strategy & planning. Prior to joining Spotlight, Cynthia served as Senior Director, Business Development at Exelixis, where she led global search & evaluation efforts and was responsible for closing multiple licensing agreements to build an innovative oncology pipeline with both small molecules and biologics therapeutic assets behind Exelixis’ flagship product Cabometyx (cabozantinib). Prior to her business development role, Cynthia was Director of Market Planning, part of the commercial organization and Cabometyx launch team, where she helped build out primary market research, competitive intelligence, and pipeline and business development analytics capabilities. Prior to Exelixis, Cynthia held roles of increasing responsibility for business analytics within the Kyprolis (carfilzomib) commercial and US launch team at Onyx and Amgen.
Cynthia received her Ph.D. in Molecular Cell Biology from Washington University in St. Louis and B.S. in Biotechnology from Huazhong University of Science and Technology.
Cynthia brings over 10 years of oncology research, pharma, and biotech experience, with core expertise in BD&L, and commercial strategy & planning. Prior to joining Spotlight, Cynthia served as Senior Director, Business Development at Exelixis, where she led global search & evaluation efforts and was responsible for closing multiple licensing agreements to build an innovative oncology pipeline with both small molecules and biologics therapeutic assets behind Exelixis’ flagship product Cabometyx (cabozantinib). Prior to her business development role, Cynthia was Director of Market Planning, part of the commercial organization and Cabometyx launch team, where she helped build out primary market research, competitive intelligence, and pipeline and business development analytics capabilities. Prior to Exelixis, Cynthia held roles of increasing responsibility for business analytics within the Kyprolis (carfilzomib) commercial and US launch team at Onyx and Amgen.
Cynthia received her Ph.D. in Molecular Cell Biology from Washington University in St. Louis and B.S. in Biotechnology from Huazhong University of Science and Technology.
Speaking In
1:00 PM - 2:00 PM
Monday, June 5
